Details of the Drug

General Information of Drug (ID: DMJQDUC)

Drug Name
Aminoguanidine
Synonyms
aminoguanidine; Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284
Indication
Disease Entry ICD 11 Status REF
Diabetic retinopathy 9B71.0 Phase 1 [1]
Insulin-resistant disorder 5A44 Discontinued in Phase 2 [2]
Rheumatoid arthritis FA20 Discontinued in Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 74.09
Topological Polar Surface Area (xlogp) -1.5
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
CH6N4
IUPAC Name
2-aminoguanidine
Canonical SMILES
C(=NN)(N)N
InChI
InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)
InChIKey
HAMNKKUPIHEESI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2146
ChEBI ID
CHEBI:40618
CAS Number
79-17-4
DrugBank ID
DB05383
TTD ID
D0V0NL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 2 (CCR2) TTFZYTO CCR2_HUMAN Antagonist [3]
Nitric-oxide synthase inducible (NOS2) TTF10I9 NOS2_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Synovial tissue
The Studied Disease Rheumatoid arthritis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 2 (CCR2) DTT CCR2 3.06E-02 0.29 0.89
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02099981) Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients in University of Minnesota - Clinical and Translational Science Institute.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018258)
3 Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
4 Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800.
5 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
6 A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
7 Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
8 Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
9 GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
10 Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
11 HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
12 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
13 WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
14 Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
17 A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
18 Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
19 CA patent application no. 841416, Method of selecting therapeutic indications.
20 Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
21 Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
22 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23 Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)